Cohance Lifesciences and Suven Pharmaceuticals formed Cohance Lifesciences Limited for $3bn.

Cohance Lifesciences, a platform formed by Advent International consolidating RA Chem Pharma, ZCL Chemicals as well as Avra Laboratories, and Suven Pharmaceuticals, an integrated, technology-driven platform committed to advancing therapeutics for a healthier world, formed Cohance Lifesciences Limited, to create a platform with enhanced capabilities and global reach, for $3bn. "The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world," Vivek Sharma, Cohance Executive Chairman.